Intended for healthcare professionals

Rapid response to:

News

Covid-19: We have good treatments for omicron, but questions remain, say doctors

BMJ 2022; 376 doi: https://doi.org/10.1136/bmj.o61 (Published 11 January 2022) Cite this as: BMJ 2022;376:o61

Read our latest coverage of the coronavirus pandemic

Rapid Response:

Re: Covid-19: We have good treatments for omicron, but questions remain, say doctors

Dear Editor

New drugs for COVID-19 infection

Today, 14.01.2022, the World Health Organisation has recommended two new drugs for COVID-19 infection.

One is baricitinib for severe or critical COVID-19 infection and the other is Sotrovimab for mild or moderate COVID-19 infection.

Newly recommended baricitinib is a Janus kinase (JAk) inhibitor, and this agent along with the corticosteroids can suppress the overstimulated immune system in severe or critical COVID-19 infection. This is an oral drug used in the treatment of rheumatoid arthritis.

Sotrovimab is a monoclonal antibody which is recommended for COVID-19 infection in older, unvaccinated, immunocompromised patients with underlying diabetes, hypertension and obesity at high risk of hospitalization.

This agent is an alternative to casirivimab-imdevimab, a monoclonal antibody cocktail in mild to moderate COVID-19 infection.

These two newly recommended drugs - baricitinib and sotrovimab - have been invited for WHO Prequalification, which assesses the quality, efficacy and safety of priority health products to increase access in lower income countries.

Competing interests: No competing interests

14 January 2022
M.A. Aleem
Emeritus Professor of Neurology * Visiting Specialist in Neurology ** Consultant Neurologist ***
The Tamilnadu Dr.M.G.R. Medical University * Dhanalakshami Srinivasan Medical College ** ABC Hospital ***
Chennai 600032* Perambalure 621212** Trichy 620018*** Tamilnadu India